Thirty years of Alzheimer's disease genetics: the implications of systematic meta-analyses
The DOI matches its Crossref record; 113 of the 113 references it cites were found in a registry or an index.
Abstract
The genetic underpinnings of Alzheimer's disease (AD) remain largely elusive despite early successes in identifying three genes that cause early-onset familial AD (those that encode amyloid precursor protein (APP) and the presenilins (PSEN1 and PSEN2)), and one genetic risk factor for late-onset AD (the gene that encodes apolipoprotein E (APOE)). A large number of studies that aimed to help uncover the remaining disease-related loci have been published in recent decades, collectively proposing or refuting the involvement of over 500 different gene candidates. Systematic meta-analyses of these studies currently highlight more than 20 loci that have modest but significant effects on AD risk. This Review discusses the putative pathogenetic roles and common biochemical pathways of some of the most genetically and biologically compelling of these potential AD risk factors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The ε4 allele of the apolipoprotein E (APOE) gene is the major genetic risk factor for AD and dementia with Lewy bodies (DLB) (1, 5, 6), whereas APOE2, a well-established longevity determinant, affords protection against the disease (7, 8).”
From APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia (2021) · cites this paper as [1]
In the citing paper
“Familial Alzheimer’s disease, which has an autosomal dominant form of inheritance and early onset, has been associated with mutations in APP, PSEN1 and PSEN2, three genes that are critical for beta amyloid (Aβ) production61.”
From Dendritic spine pathology in neuropsychiatric disorders (2011) · cites this paper as [61]
Citations
Cites
Meta-analysis in clinical trials
DerSimonian, R., & Laird, N. (1986) · Controlled Clinical Trials · doi:10.1016/0197-2456(86)90046-2 · Cited by 39,552
Goate, A., Chartier-Harlin, M.-C., Mullan, M., Brown, J., Crawford, F., Fidani, L., Giuffra, L., Haynes, A., Irving, N., James, L., et al. (1991) · Nature · doi:10.1038/349704a0 · Cited by 4,659
Strittmatter, W. J., Saunders, A. M., Schmechel, D., Pericak-Vance, M., Enghild, J., Salvesen, G. S., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.5.1977 · Cited by 4,268
Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease
Sherrington, R., Rogaev, E. I., Liang, Y., Rogaeva, E. A., Levesque, G., Ikeda, M., Chi, H., Lin, C., Li, G., Holman, K., et al. (1995) · Nature · doi:10.1038/375754a0 · Cited by 4,051
Self-citationAssociation of apolipoprotein E allele ϵ4 with late‐onset familial and sporadic Alzheimer's disease
Saunders, A. M., Strittmatter, W. J., Schmechel, D., St. George-Hyslop, P. H., Pericak-Vance, M. A., Joo, S. H., Rosi, B. L., Gusella, J. F., Crapper-MacLachlan, D. R., Alberts, M. J., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1467 · Cited by 3,786
Genome-wide association studies for complex traits: consensus, uncertainty and challenges
McCarthy, M. I., Abecasis, G. R., Cardon, L. R., Goldstein, D. B., Little, J., Ioannidis, J. P. A., & Hirschhorn, J. N. (2008) · Nature Reviews Genetics · doi:10.1038/nrg2344 · Cited by 2,891
Candidate gene for the chromosome 1 familial Alzheimer’s disease locus
Levy-Lahad, E., Wasco, W., Poorkaj, P., Romano, D. M., Oshima, J., Pettingell, W. H., Yu, C.-E., Jondro, P. D., Schmidt, S. D., Wang, K., et al. (1995) · Science · doi:10.1126/science.7638622 · Cited by 2,577
Self-citationTau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 1×
“Despite the lack of MAPT mutations in AD, it is likely that tau dysfunction still contributes to AD ris”
BackgroundRogaev, E. I., Sherrington, R., Rogaeva, E. A., Levesque, G., Ikeda, M., Liang, Y., Chi, H., Lin, C., Holman, K., Tsuda, T., et al. (1995) · Nature · doi:10.1038/376775a0 · Cited by 2,052
Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database
Bertram, L., McQueen, M. B., Mullin, K., Blacker, D., & Tanzi, R. E. (2007) · Nature Genetics · doi:10.1038/ng1934 · Cited by 1,857 · cited 1×
“, none of these candidates has been proved to consistently influence disease risk or onset age in more than a handful of sample”
BackgroundSelf-citation
Research works printed but not linked: 1
- Meyer, J. M. & Breitner, J. C. Multiple threshold model for the onset of Alzheimer's disease in the NAS-NRC twin panel. Am. J. Med. Genet. 81, 92–97 (1998). · DOI · Paper page
Cited by
Items 101–200 of 754
Sanchez‐Mut, J. V., Aso, E., Heyn, H., Matsuda, T., Bock, C., Ferrer, I., & Esteller, M. (2014) · Hippocampus · doi:10.1002/hipo.22245 · Cited by 112
Systemic and CNS Inflammation Crosstalk: Implications for Alzheimer’s Disease
Paouri, E., & Georgopoulos, S. (2019) · Current Alzheimer Research · doi:10.2174/1567205016666190321154618 · Cited by 110
Zhao, Y., Dang, M., Zhang, W., Lei, Y., Ramesh, T., Veeraraghavan, V. P., & Hou, X. (2020) · Journal of Functional Foods · doi:10.1016/j.jff.2020.104009 · Cited by 130
Maesako, M., Uemura, K., Kubota, M., Kuzuya, A., Sasaki, K., Asada, M., Watanabe, K., Hayashida, N., Ihara, M., Ito, H., et al. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.028 · Cited by 128
“Masato Maesako 1 , Kengo Uemura 2 , Masakazu Kubota 1 , Akira Kuzuya 2 , Kazuki Sasaki 1 , Megumi Asada 1 , Kiwamu Watanabe 2 , Naoko Hayashida 1 , Masafumi Ihara 2 , Hidefumi Ito 2 , Shun Shimohama 3 , Takeshi Kihara 1 and Ayae Kinoshita 1* 1.”
BackgroundAPOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, C.-C., Murray, M. E., Li, X., Zhao, N., Wang, N., Heckman, M. G., Shue, F., Martens, Y., Li, Y., Raulin, A.-C., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc9375 · Cited by 108
A rapid and cost-effective method for genotyping apolipoprotein E gene polymorphism
Zhong, L., Xie, Y.-Z., Cao, T.-T., Wang, Z., Wang, T., Li, X., Shen, R.-C., Xu, H., Bu, G., & Chen, X.-F. (2016) · Molecular Neurodegeneration · doi:10.1186/s13024-016-0069-4 · Cited by 106
Protein aggregation as a paradigm of aging
Lindner, A. B., & Démarez, A. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.06.005 · Cited by 127
Grimm, S., Hoehn, A., Davies, K. J., & Grune, T. (2011) · Free Radical Research · doi:10.3109/10715762.2010.512040 · Cited by 107
Ocular Biomarkers for Early Detection of Alzheimer's Disease
Frost, S., Martins, R. N., & Kanagasingam, Y. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100819 · Cited by 106
“Also, a recent meta-analysis has found more than 20 genes that have a significant effect on AD risk [42].”
Thal, D. R., Papassotiropoulos, A., Saido, T. C., Griffin, W. S. T., Mrak, R. E., Kölsch, H., Tredici, K. D., Attems, J., & Ghebremedhin, E. (2010) · Acta Neuropathologica · doi:10.1007/s00401-010-0707-9 · Cited by 103
“This polymorphism has been discussed previously as being associated with AD [40], but other authors could not replicate that group’s findings [7, 8].”
BackgroundResultZhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A. M., Shen, X., Ran, C., Elmaleh, D. R., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-19641-2 · Cited by 99
Self-citationSchjeide, B.-M. M., Schnack, C., Lambert, J.-C., Lill, C. M., Kirchheiner, J., Tumani, H., Otto, M., Tanzi, R. E., Lehrach, H., Amouyel, P., et al. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.196 · Cited by 82
“CSF-A 42 and total tau protein levels were determined using commercially available sandwich enzyme-linked immunosorbent assays Innotest -amyloid[1-42] and hTau Ag kits; Innogenetics, Gent, Belgium following the manufacturers instructions as previously described elsewhere.”
MethodSelf-citationGenetic variants in Alzheimer disease — molecular and brain network approaches
Gaiteri, C., Mostafavi, S., Honey, C. J., De Jager, P. L., & Bennett, D. A. (2016) · Nature Reviews Neurology · doi:10.1038/nrneurol.2016.84 · Cited by 96
Deciphering complex mechanisms in neurodegenerative diseases: the advent of systems biology
Noorbakhsh, F., Overall, C. M., & Power, C. (2009) · Trends in Neurosciences · doi:10.1016/j.tins.2008.10.003 · Cited by 100
Presenilins function in ER calcium leak and Alzheimer's disease pathogenesis
Supnet, C., & Bezprozvanny, I. (2011) · Cell Calcium · doi:10.1016/j.ceca.2011.05.013 · Cited by 95
“Mutations in the genes encoding presenilin-1 (PSEN1), presenilin-2 (PSEN2) and amyloid precursor protein (APP) account for more than 50% of autosomal-dominant FAD cases (Bergmans and De Strooper, 2010; Bertram and Tanzi, 2008; Hardy, 2009; Hardy and Selkoe, 2002).”
BackgroundGFAPδ in radial glia and subventricular zone progenitors in the developing human cortex
Middeldorp, J., Boer, K., Sluijs, J. A., De Filippis, L., Encha-Razavi, F., Vescovi, A. L., Swaab, D. F., Aronica, E., & Hol, E. M. (2010) · Development · doi:10.1242/dev.041632 · Cited by 95
“, 2002), which are associated with genetic forms of Alzheimer’s disease (Bertram and Tanzi, 2008).”
BackgroundBello-Chavolla, O. Y., Antonio-Villa, N. E., Vargas-Vázquez, A., Ávila-Funes, J. A., & Aguilar-Salinas, C. A. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190129155654 · Cited by 94
A SERS-Based Sandwich Assay for Ultrasensitive and Selective Detection of Alzheimer’s Tau Protein
Zengin, A., Tamer, U., & Çaykara, T. (2013) · Biomacromolecules · doi:10.1021/bm400968x · Cited by 104
Selecting a Mouse Model of Alzheimer’s Disease
Chin, J. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-744-0_13 · Cited by 91
MicroRNA networks surrounding APP and amyloid-β metabolism — Implications for Alzheimer's disease
Schonrock, N., Matamales, M., Ittner, L. M., & Götz, J. (2012) · Experimental Neurology · doi:10.1016/j.expneurol.2011.11.013 · Cited by 93
“Here, autosomal dominant mutations have been identified in three genes, in APP itself, as well as in presenilin 1 (PSEN1) and 2 (PSEN2) both of which encode a component of the enzyme complex that is required to generate Aβ (Bertram and Tanzi, 2008).”
Jiang, J., & Jiang, H. (2015) · Molecular Medicine Reports · doi:10.3892/mmr.2015.3424 · Cited by 97
“The genes encoding APP, presenilin (PSEN)-1 and PSEN-2, have been demonstrated to harbor autosomal dominant mutations associated with AD, while the presence of the APOE‑4 allele is considered a risk factor for the development of AD (Table I) (67).”
Foster, T. C., Kyritsopoulos, C., & Kumar, A. (2016) · Behavioural Brain Research · doi:10.1016/j.bbr.2016.05.012 · Cited by 99
“For these genes, a progressive cognitive decline begins around the fourth or fifth decade of life [3-5].”
Association of Reproductive History With Brain MRI Biomarkers of Dementia Risk in Midlife
Schelbaum, E., Loughlin, L., Jett, S., Zhang, C., Jang, G., Malviya, N., Hristov, H., Pahlajani, S., Isaacson, R., Dyke, J. P., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012941 · Cited by 105
“In a cohort of well-characterized midlife women at risk for AD, with the use of voxel-based morphometry and VOI analysis, some reproductive history indicators signaling longer estrogen exposure were associated with largerMRI-derived GMV in brain regions vulnerable to cognitive aging and AD.”
ResultInfluentialSubash, S., Essa, M. M., Al-Asmi, A., Al-Adawi, S., Vaishnav, R., Braidy, N., Manivasagam, T., & Guillemin, G. J. (2014) · Journal of Traditional and Complementary Medicine · doi:10.4103/2225-4110.139107 · Cited by 90
“functions in the elderly population.[1] It affects millions of people”
BackgroundReelin-mediated signaling in neuropsychiatric and neurodegenerative diseases
Knuesel, I. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.04.002 · Cited by 89
“Among the more than 500 genes associated with late-onset AD, only apolipoprotein E (apoE) e4 has been proved to consistently influence disease risk, age at onset, amyloid burden and cognitive performance (Corder et al., 1993; Schmechel et al., 1993; Bertram and Tanzi, 2008).”
Placanica, L., Zhu, L., & Li, Y.-M. (2009) · PLoS ONE · doi:10.1371/journal.pone.0005088 · Cited by 88
“in nature and has no known genetic basis [3].”
BackgroundChen, L. H., Kao, P. Y. P., Fan, Y. H., Ho, D. T. Y., Chan, C. S. Y., Yik, P. Y., Ha, J. C. T., Chu, L. W., & Song, Y.-Q. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.016 · Cited by 87
“result of association between APOE 4 and an increased disease risk has been confirmed in different ethnic populations based on candidate gene approaches as well as genome wide association studies (GWAS) (Bertram and Tanzi, 2008).”
BackgroundYang, S.-H., Li, W., Sumien, N., Forster, M. J., Simpkins, J. W., & Liu, R. (2015) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.10.005 · Cited by 94
“…isoforms of Apolipoprotein E (APOE), a pivotal regulator for cholesterol metabolism, with the e4 allele as the strongest genetic risk factor for AD (Bertram and Tanzi, 2008; Corder et al., 1993), providing strong evidence that lipid metabolism dysfunction may be involved in AD pathophysiology…”
BackgroundHeilig, E. A., Xia, W., Shen, J., & Kelleher, R. J. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.116962 · Cited by 87
The Patterns of Inheritance in Early-Onset Dementia: Alzheimer’s Disease and Frontotemporal Dementia
Jarmolowicz, A. I., Chen, H.-Y., & Panegyres, P. K. (2015) · American Journal of Alzheimer's Disease & Other Dementias® · doi:10.1177/1533317514545825 · Cited by 86
Heritability of Different Forms of Memory in the Late Onset Alzheimer's Disease Family Study
Wilson, R. S., for the National Institute on Aging Late-Onset Alzheimer's Disease Genetics Study, Barral, S., Lee, J. H., Leurgans, S. E., Foroud, T. M., Sweet, R. A., Graff-Radford, N., Bird, T. D., Mayeux, R., et al. (2011) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-101515 · Cited by 86
“Although the genetic contribution to AD is thought to be substantial, to date relatively few genetic variants associated with the disease have been identified and subsequently replicated in independent samples [3].”
Modes of Aβ toxicity in Alzheimer’s disease
Götz, J., Eckert, A., Matamales, M., Ittner, L. M., & Liu, X. (2011) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-011-0750-2 · Cited by 83
Sönmez, F., Kurt, B. Z., Gazioğlu, I., Basile, L., Dağ, A., Cappello, V., Ginex, T., Küçükislamoğlu, M., & Guccione, S. (2017) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2016.1250753 · Cited by 83
“3-acetylcoumarin (2) was synthesized from salicylaldehyde (1) according to the literature(46), and then it was brominated by molecular bromine in chloroform.”
BackgroundMethodInfluentialTseveleki, V., Rubio, R., Vamvakas, S.-S., White, J., Taoufik, E., Petit, E., Quackenbush, J., & Probert, L. (2010) · Genomics · doi:10.1016/j.ygeno.2010.04.004 · Cited by 83
“Mutations or duplications in three genes that are important for regulating Aβ production, amyloid precursor protein (APP), presenelin (PSEN)1 and PSEN2, lead to early-onset familial AD while polymorphisms in the gene encoding apolipoprotein E (APOE) are a genetic risk factor for late-onset AD [1].”
BackgroundChen, J., & Chern, Y. (2010) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-13443-2_10 · Cited by 92
Nho, K., Corneveaux, J. J., Kim, S., Lin, H., Risacher, S. L., Shen, L., Swaminathan, S., Ramanan, V. K., Liu, Y., Foroud, T., et al. (2013) · Molecular Psychiatry · doi:10.1038/mp.2013.24 · Cited by 82
Kawahara, M., Ohtsuka, I., Yokoyama, S., Kato-Negishi, M., & Sadakane, Y. (2011) · International Journal of Alzheimer’s Disease · doi:10.4061/2011/304583 · Cited by 81
“Presenilins have been revealed to be γ-secretases [13], and their mutations influence the production of AβP and its neurotoxicity [14].”
BackgroundClinicopathological Outcomes of Prospectively Followed Normal Elderly Brain Bank Volunteers
Dugger, B. N., Hentz, J. G., Adler, C. H., Sabbagh, M. N., Shill, H. A., Jacobson, S., Caviness, J. N., Belden, C., Driver-Dunckley, E., Davis, K. J., et al. (2014) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000046 · Cited by 80
Malishev, R., Shaham‐Niv, S., Nandi, S., Kolusheva, S., Gazit, E., & Jelinek, R. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.6b00438 · Cited by 81
Nelson, O., Supnet, C., Liu, H., & Bezprozvanny, I. (2010) · Journal of Alzheimer's Disease · doi:10.3233/jad-2010-100159 · Cited by 79
“Mutations in the genes encoding presenilin 1 (PS1), PS2 and amyloid-β protein precursor (A β PP) account for the majority of monogenic FAD cases [1,2, 4,5].”
APOE and neuroenergetics: an emerging paradigm in Alzheimer's disease
Wolf, A. B., Caselli, R. J., Reiman, E. M., & Valla, J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.10.011 · Cited by 79
“Genetically, APOE ε4 is associated with dramatically increased risk, APOE ε3 is associated with neutral risk, and APOE ε2 is associated with decreased risk (Bertram and Tanzi, 2008; Gomez-Isla et al., 1996).”
BackgroundIslet amyloid polypeptide: Another key molecule in Alzheimer’s pathogenesis?
Zhang, Y., & Song, W. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2017.03.001 · Cited by 83
“For example, the apolipoprotein E-e4 (ApoE-e4) is identified as the strongest genetic risk factor (Bertram and Tanzi, 2008; Corder et al., 1993).”
BackgroundSchürmann, B., Bermingham, D. P., Kopeikina, K. J., Myczek, K., Yoon, S., Horan, K. E., Kelly, C. J., Martin-de-Saavedra, M. D., Forrest, M. P., Fawcett-Patel, J. M., et al. (2020) · Molecular Psychiatry · doi:10.1038/s41380-019-0407-3 · Cited by 72
Blennow, K., & Zetterberg, H. (2015) · Frontiers in Neuroscience · doi:10.3389/fnins.2015.00345 · Cited by 76
“The Putative APOE Dependence of CSF Aβ42 The apolipoprotein E (APOE) ε4 allele is the main genetic risk factor for AD (Bertram and Tanzi, 2008).”
Neuropathological Mechanisms Associated with Pesticides in Alzheimer’s Disease
Tang, B. L. (2020) · Toxics · doi:10.3390/toxics8020021 · Cited by 85
“Mutations in APP and the presenilins (PS) (which are the catalytic components of γ-secretase [17,18]) that underlie familial and early-onset AD [4,19,20] invariably cause an increase in Aβ production.”
BackgroundHerpes Simplex Virus Dances with Amyloid Precursor Protein while Exiting the Cell
Cheng, S.-B., Ferland, P., Webster, P., & Bearer, E. L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0017966 · Cited by 77
“Since altered APP is a known risk factor for Alzheimer’s disease [21,22], which has been linked to transport defects [23,24,25,26], interactions of APP with HSV1 are”
BackgroundMidlife predictors of Alzheimer's disease
Bendlin, B. B., Carlsson, C. M., Gleason, C. E., Johnson, S. C., Sodhi, A., Gallagher, C. L., Puglielli, L., Engelman, C. D., Ries, M. L., Xu, G., et al. (2010) · Maturitas · doi:10.1016/j.maturitas.2009.12.014 · Cited by 78
“Of the single nucleotide polymorphisms (SNPs) associated with AD risk, three promising candidates include a variant of CLU, encoding clusterin, on chromosome 8; a variant of CR1, encoding the complement component (3b/4b) receptor 1, on chromosome 1 [20]; and variants near a gene encoding the PICALM protein [21] [see B…”
Characterization of AD-like phenotype in aged APPSwe/PS1dE9 mice
Huang, H., Nie, S., Cao, M., Marshall, C., Gao, J., Xiao, N., Hu, G., & Xiao, M. (2016) · AGE · doi:10.1007/s11357-016-9929-7 · Cited by 85
Association of Aβ with ceramide-enriched astrosomes mediates Aβ neurotoxicity
Elsherbini, A., Kirov, A. S., Dinkins, M. B., Wang, G., Qin, H., Zhu, Z., Tripathi, P., Crivelli, S. M., & Bieberich, E. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00931-8 · Cited by 72
“Introduction Aβ plaque deposits and tau neurofibrillary tangle formation are hallmarks of AD [2, 62].”
BackgroundLista, S., Garaci, F. G., Ewers, M., Teipel, S., Zetterberg, H., Blennow, K., & Hampel, H. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2013.04.506 · Cited by 76
“Individuals with one ε4 allele are 3–4 times more likely to develop AD than those without ε4 alleles [30].”
BackgroundSun, M., Shen, X., & Yun-zhi, M. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.109492 · Cited by 78
Nanoparticle-mediated approaches for Alzheimer’s disease pathogenesis, diagnosis, and therapeutics
Hettiarachchi, S. D., Zhou, Y., Seven, E., Lakshmana, M. K., Kaushik, A. K., Chand, H. S., & Leblanc, R. M. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.10.034 · Cited by 76
A Review on Potential Footprints of Ferulic Acid for Treatment of Neurological Disorders
Thapliyal, S., Singh, T., Handu, S. S., Bisht, M., Kumari, P., Arya, P., Srivastava, P., & Ravi, G. (2021) · Neurochemical Research · doi:10.1007/s11064-021-03257-6 · Cited by 87
Li, N., & Liu, G.-T. (2010) · Acta Pharmacologica Sinica · doi:10.1038/aps.2010.3 · Cited by 79
Xicota, L., Rodriguez-Morato, J., Dierssen, M., & de la Torre, R. (2016) · Current Drug Targets · doi:10.2174/1389450116666150825113655 · Cited by 76
“The inheritance of the ε4 allele of apolipoprotein E (ApoE4) is a well-established genetic risk factor for late onset sporadic AD [23, 24] although its mechanism of action is not well established [25].”
BackgroundMolecular Insights into the Pathogenesis of Alzheimer's Disease and Its Relationship to Normal Aging
Podtelezhnikov, A. A., Tanis, K. Q., Nebozhyn, M., Ray, W. J., Stone, D. J., & Loboda, A. P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0029610 · Cited by 75
“familial AD, the cause of disease is autosomal dominant mutations in Ab precursor protein (APP) or the Ab-producing enzymes presenilins (PSEN1 or PSEN2), which are all thought to lead to increased levels of aggregated Ab [9,10,16].”
BackgroundPerkins, M., Wolf, A. B., Chavira, B., Shonebarger, D., Meckel, J. P., Leung, L., Ballina, L., Ly, S., Saini, A., Jones, T. B., et al. (2016) · Journal of Alzheimer's Disease · doi:10.3233/jad-151205 · Cited by 75
“Keywords: Alzheimer’s disease, APOE, biomarker, energy metabolism, glucose, ketones, mitochondria, monocarboxylate, neurodegeneration, posterior cingulate”
Genetic influences on blood lipids and cardiovascular disease risk: tools for primary prevention
Ordovas, J. M. (2009) · The American Journal of Clinical Nutrition · doi:10.3945/ajcn.2009.27113e · Cited by 74
“APOE may be a marker for CVD risk and dietary response, but the association between APOE4 and Alzheimer’s (85) needs to be taken into consideration.”
BackgroundHe, P., Cheng, X., Staufenbiel, M., Li, R., & Shen, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055091 · Cited by 73
“Senile neuritic plaques are a hallmark of AD brains [47,58].”
BackgroundInfluentialViayna, E., Sabaté, R., & Muñoz‐Torrero, D. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/15680266113139990139 · Cited by 85
“…mutations or polymorphisms in genes that result in increased production of A or of its amyloidogenicity (either increased levels of A42 or increased ratio A42/A40), namely the genes of APP, apolipoprotein E, presenilin 1, and presenilin 2, in chromosomes 21, 19, 14, and 1, respectively [18].”
BackgroundBridging Physiology and Pathology in AD
Kim, D., & Tsai, L. (2009) · Cell · doi:10.1016/j.cell.2009.05.042 · Cited by 74
“Interestingly, a specific polymorphism in PrP appears to reduce the risk of developing AD (Bertram and Tanzi, 2008).”
BackgroundAneuploidy, chromosomal missegregation, and cell cycle reentry in Alzheimer's disease
Zekanowski, C., & Wojda, U. (2009) · Acta Neurobiologiae Experimentalis · doi:10.55782/ane-2009-1748 · Cited by 73
“This suggests that all simple pathogenic loci have been identified, and that other familial clustering is more likely to be oligogenic or epigenetic rather than monogenic in etiology (Bertram and Tanzi 2008).”
BackgroundEndoplasmic reticulum calcium stores in dendritic spines
Segal, M., & Korkotian, E. (2014) · Frontiers in Neuroanatomy · doi:10.3389/fnana.2014.00064 · Cited by 86
“Mutations in three major genes implicated in beta amyloid (Aβ) metabolism, amyloid precursor protein (APP) and presenilin1 (PS1) have been associated to familial AD with an autosomal dominant form of inheritance and early onset of the disease (Bertram and Tanzi, 2008; Bertram et al., 2010).”
Adav, S. S., & Sze, S. K. (2016) · Molecular Brain · doi:10.1186/s13041-016-0272-9 · Cited by 70
Membrane trafficking in neuronal maintenance and degeneration
Wang, D., Chan, C., Cherry, S., & Hiesinger, P. R. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1201-4 · Cited by 77
“All three genes are directly linked to the generation of amyloid b (Ab) peptides [64, 65].”
BackgroundSphingolipid-Enriched Extracellular Vesicles and Alzheimer’s Disease: A Decade of Research
Dinkins, M. B., Wang, G., & Bieberich, E. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-160567 · Cited by 72
“Even though AD was first described in 1906 by Dr. Alois Alzheimer, practically everything we currently understand about the molecular basis of AD has been uncovered in the last twenty years [1–5].”
Longer Duration of Hormonal Contraceptive Use Predicts Better Cognitive Outcomes Later in Life
Egan, K. R., & Gleason, C. E. (2012) · Journal of Women s Health · doi:10.1089/jwh.2012.3522 · Cited by 74
“In our aging population, the incidence of Alzheimer’s disease (AD) and dementia is increasing.(1,2) The social and economic burden these diseases place on the healthcare system, patients, and family members makes them a significant public health concern.”
BackgroundChlamydia pneumoniae infection and Alzheimer’s disease: a connection to remember?
Shima, K., Kuhlenbäumer, G., & Rupp, J. (2010) · Medical Microbiology and Immunology · doi:10.1007/s00430-010-0162-1 · Cited by 83
“By contrast, late-onset AD (LOAD) usually occurs after the age of 65 and is associated with the apolipoprotein E- 4 (APOE- 4) allele as a major risk factor [4].”
BackgroundApoE ε4 is associated with eIF2α phosphorylation and impaired learning in young mice
Segev, Y., Michaelson, D. M., & Rosenblum, K. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.020 · Cited by 77
Bryson, G. L., Wyand, A., Wozny, D., Rees, L. M., Taljaard, M., & Nathan, H. (2011) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/s12630-010-9446-6 · Cited by 75
General anesthetics and β-amyloid protein
Xie, Z., & Xu, Z. (2012) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.08.002 · Cited by 75
“The genes encoding the APP, presenilin-1 and presenilin-2 have been shown to harbor autosomal dominant AD gene, and the gene APOE-4 is a risk factor of AD (Bertram and Tanzi, 2008).”
BackgroundResultAssociation between COMT Val158Met and psychiatric disorders: A comprehensive meta‐analysis
Taylor, S. J. (2017) · American Journal of Medical Genetics Part B Neuropsychiatric Genetics · doi:10.1002/ajmg.b.32556 · Cited by 97
“…there are genetic differences between early versus late onset forms of disorders, including OCD, schizophrenia, bipolar disorder, Alzheimer’s disease, and other disorders (Bertram and Tanzi, 2008; Hamshere et al., 2009; Kendler, Fiske, Gardner, & Gatz, 2009; Schürhoff et al., 2004; Taylor, 2011a).”
BackgroundWitoelar, A., Rongve, A., Almdahl, I. S., Ulstein, I. D., Engvig, A., White, L. R., Selbæk, G., Stordal, E., Andersen, F., Brækhus, A., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-36429-6 · Cited by 69
Kim, C.-B., Choi, Y. Y., Song, W. K., & Song, K. (2013) · Journal of Biomedical Optics · doi:10.1117/1.jbo.19.5.051205 · Cited by 72
Peptides as Potential Therapeutics for Alzheimer’s Disease
Ribarič, S. (2018) · Molecules · doi:10.3390/molecules23020283 · Cited by 67
Pasinetti, G. M. (2012) · Planta Medica · doi:10.1055/s-0032-1315377 · Cited by 78
Wei, G., Chen, Y., Chen, D., Lai, X., Liu, D., Deng, R., Zhou, J., Zhang, S., Li, Y.-W., Lii, H., et al. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-120865 · Cited by 67
Bosch, M. E., Dodiya, H. B., Michalkiewicz, J., Lee, C., Shaik, S. M., Weigle, I. Q., Zhang, C., Osborn, J., Nambiar, A., Patel, P., et al. (2024) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00700-w · Cited by 70
“…neurodegenerative disorder that is pathologically characterized by the presence of abundant amyloid plaques, composed of amyloid-β (Aβ) peptides, and neurofibrillary tangles, composed of hyperphosphorylated/aggregated forms of tau in the cortex and hippocampus of affected individuals [1–3].”
BackgroundSelf-citationAmyloid and Alzheimer's Disease: Inside and Out
Tam, J. H. K., & Pasternak, S. H. (2012) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100013408 · Cited by 66
Insights into lncRNAs in Alzheimer’s disease mechanisms
Li, D., Zhang, J., Li, X., Chen, Y., Feng, Y., & Liu, Q. (2020) · RNA Biology · doi:10.1080/15476286.2020.1788848 · Cited by 71
Novel Anti-Alzheimer’s Therapeutic Molecules Targeting Amyloid Precursor Protein Processing
Uddin, M. S., Kabir, M. T., Jeandet, P., Mathew, B., Ashraf, G. M., Perveen, A., Bin-Jumah, M. N., Mousa, S. A., & Abdel‐Daim, M. M. (2020) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2020/7039138 · Cited by 70
Four Decades of Neurodegenerative Disease Research: How Far We Have Come!
Young, A. B. (2009) · Journal of Neuroscience · doi:10.1523/jneurosci.3767-09.2009 · Cited by 72
“The skull of a transgenic Alzheimer’s mouse is burred to a thin translucent covering so the brain underneath can be imaged, and intravenous thioflavin is used to label the plaques.”
BackgroundInfluentialNoh, H. J., Tang, R., Flannick, J., O’Dushlaine, C., Swofford, R., Howrigan, D., Genereux, D. P., Johnson, J., van Grootheest, G., Grünblatt, E., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-00831-x · Cited by 64
Mielke, M. M. (2020) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2019.030023 · Cited by 63
“Compared to noncarriers, carriers of one ε4 allele are 3–4 times more likely to develop AD, while the risk for those with two ε4 alleles is considerably higher (83, 86).”
BackgroundFenesi, B., Fang, H., Kovacevic, A., Oremus, M., Raina, P., & Heisz, J. J. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160424 · Cited by 64
“Carriers of a single APOE ε 4 allele are estimated to have a three to four fold increased risk of disease over age-matched non-carriers [13].”
Capillary CAA and perivascular Aβ-deposition: Two distinct features of Alzheimer's disease pathology
Attems, J., Yamaguchi, H., Saido, T. C., & Thal, D. R. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.030 · Cited by 63
“Apolipoprotein E (apoE) is involved in physiological perivascular clearance of the extracellular fluid [13] and its APOE ε4 allele has been reported to be a major risk factor for sporadic AD [14,15].”
The dark sides of amyloid in Alzheimer's disease pathogenesis
Sorrentino, P., Iuliano, A., Polverino, A., Jacini, F., & Sorrentino, G. (2014) · FEBS Letters · doi:10.1016/j.febslet.2013.12.038 · Cited by 63
“risk factor for LOAD [26], APOE e3 is associated with neutral risk and APOEe2 is associated with decreased risk [134].”
BackgroundProteinopathies, neurodegenerative disorders with protein aggregation-based pathology
Shelkovnikova, T. A., Kulikova, A. A., Tsvetkov, P. O., Peters, O. M., Бачурин, С. О., Buchman, V. L., & Ninkina, N. N. (2012) · Molecular Biology · doi:10.1134/s0026893312020161 · Cited by 66
Giacomelli, C., Daniele, S., & Martini, C. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.01.017 · Cited by 79
Alzheimer’s disease and the autophagic-lysosomal system
Chung, K. M., Hernández, N., Sproul, A. A., & Yu, W. H. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2018.05.017 · Cited by 63
Differential effects of the ApoE4 genotype on brain structure and function
Matura, S., Prvulovic, D., Jurcoane, A., Hartmann, D., Miller, J., Scheibe, M., O’Dwyer, L., Oertel‐Knöchel, V., Knöchel, C., Reinke, B., et al. (2013) · NeuroImage · doi:10.1016/j.neuroimage.2013.11.042 · Cited by 70
“The ε4 allele frequency is approximately 15% in the general population but is 40% in patients with AD (Bertram and Tanzi, 2008).”
BackgroundSamadi, A., Estrada, M., Pérez, C., Rodríguez-Franco, M. I., Iriepa, I., Moraleda, I., Chioua, M., & Marco, J. L. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.09.030 · Cited by 68
Chapter 9 Alzheimer's Disease Genetics
Bertram, L. (2009) · International review of neurobiology · doi:10.1016/s0074-7742(09)00409-7 · Cited by 72
Self-citationMuraoka, S., Jedrychowski, M. P., Iwahara, N., Abdullah, M., Onos, K. D., Keezer, K. J., Hu, J., Ikezu, S., Howell, G. R., Gygi, S. P., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.0c00934 · Cited by 61
Silva, D., Chioua, M., Samadi, A., Carreiras, M. C., Jimeno, M. L., Mendes, E., Ríos, C. D. L., Romero, A., Villarroya, M., López, M. G., et al. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.05.068 · Cited by 62
The Role of the p75 Neurotrophin Receptor in Cholinergic Dysfunction in Alzheimer's Disease
Coulson, E. J., May, L. M., Sykes, A. M., & Hamlin, A. S. (2009) · The Neuroscientist · doi:10.1177/1073858408331376 · Cited by 61
Watanabe, K., Uemura, K., Asada, M., Maesako, M., Akiyama, H., Shimohama, S., Takahashi, R., & Kinoshita, A. (2015) · Molecular Brain · doi:10.1186/s13041-015-0174-2 · Cited by 62
“A β is widely considered to be the primary pathological agent in AD [3, 5, 10] because mutations of the genes that encode APP and presenilin, which are enzymes related to the cleavage of A β , are known to cause early-onset familial AD [11, 12].”
BackgroundDecoding the non-coding RNAs in Alzheimer’s disease
Schönrock, N., & Götz, J. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1125-z · Cited by 63
“Autosomal dominant mutations have been identified in three genes; in APP itself as well as in presenilin 1 (PSEN1) and 2 (PSEN2) both of which encode a component of the c-secretase complex [15].”
Parkinsonism in viral, paraneoplastic, and autoimmune diseases
Xing, F., Marsili, L., & Truong, D. D. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.120014 · Cited by 63
Protein aggregation and its affecting mechanisms in neurodegenerative diseases
Wu, J., Wu, J., Chen, T., Cai, J., & Ren, R. (2024) · Neurochemistry International · doi:10.1016/j.neuint.2024.105880 · Cited by 69
“In general, mutations close to the N-terminal end of the A β sequence cause an increase of A β production, while mutations close to the C-terminal end of the sequence cause an increase of the A β 42/A β 40 ratio (Bertram and Tanzi, 2008; Benilova et al., 2012).”
Metadata
- Authors
- Bertram, L., & Tanzi, R. E.
- Affiliations
- Harvard University (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Bertram, Lars
- Venue
- Nature Reviews Neuroscience
- Published
- 2008-10
- Volume
- 9
- Issue
- 10
- Pages
- 768-778
- ISSN
- 1471-003X (ISSN-L)
- 1471-0048
- OpenAlex
- W2018342879
- Cited by
- 747
- References
- 113
- Citations by year
- 2026: 12 · 2025: 16 · 2024: 25 · 2023: 21 · 2022: 33 · 2021: 26 · 2020: 29 · 2019: 34 · 2018: 41 · 2017: 46 · 2016: 37 · 2015: 41 · 2014: 46 · 2013: 59 · 2012: 62
- FWCI
- 7.89
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Neuroscience (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute on Aging (5R01-AG23667, R01AG023667)
- National Institute of Mental Health (5R37MH60009, R37MH060009)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic Associations and Epidemiology
- Keywords
- Alzheimer's disease genetics, genetic risk factors, candidate genes, meta-analysis, amyloid precursor protein, presenilin 1, presenilin 2, apolipoprotein E, early-onset familial Alzheimer's disease, late-onset Alzheimer's disease, disease pathology, metabolic pathways
- MeSH terms
- Alzheimer Disease, Animals, Apolipoproteins E, Brain Chemistry, Humans, Mutation, Risk Factors, Meta-Analysis as Topic, Amyloid beta-Protein Precursor, Genetic Predisposition to Disease, Presenilins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.